Geode Capital Management
RNAZ icon

Geode Capital Management’s TransCode Therapeutics RNAZ Stock Holding History

Geode Capital Management’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$110K Buy
+12,740
New +$119K ﹤0.01% 4111
2024
Q4 		– Sell
-132
Closed -$69.5K – 4501
2024
Q3 		$69.5K Buy
132
+90
+214% +$36.4K ﹤0.01% 4193
2024
Q2 		$38.6K Buy
+42
New +$37.4K ﹤0.01% 4332
2024
Q1 		– Sell
-1
Closed -$8.61K – 4633
2023
Q4 		$8.61K Buy
+1
New +$11.2K ﹤0.01% 4600
2023
Q2 		– Hold
0
– -$25.6K – 4779
2023
Q1 		– Hold
0
– – – 4657
2022
Q4 		– Hold
0
– – – 4586
2022
Q3 		– Hold
0
– – – 4631
2022
Q2 		– Hold
0
– – – 4610
2022
Q1 		– Hold
0
– – – 4370
2021
Q4 		– Hold
0
– – – 4521
2021
Q3 		– Hold
0
– – – 4779

Other funds holding RNAZ

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Geode Capital Management's RNAZ Position: Q1 2026 in Review

Geode Capital Management opened a new position in TransCode Therapeutics (RNAZ) in Q1 2026: 12,740 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #4111 among its holdings. This is a return to the name: Geode Capital Management previously reported a position in RNAZ as recently as Q3 2024.

Geode Capital Management first reported a position in RNAZ in Q4 2023 and has held it in 4 quarters since. 8 funds tracked by Wall St. Rank hold RNAZ as of Q1 2026.

  • Geode Capital Management held 12,740 shares of TransCode Therapeutics worth $110K as of Q1 2026.
  • TransCode Therapeutics was a new Geode Capital Management position in Q1 2026.
  • TransCode Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4111 holding.
  • Geode Capital Management first reported a position in TransCode Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • 8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.